🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cómo sería - Alejandro Sanz, Manuel Turizo

Checkout new publication by Dr. Amir H Hamrahian, director of our Adrenal Center, in NEJM Phase 2a Study of Baxdrostat in Primary Aldosteronism Johns Hopkins Medicine Johns Hopkins Department of Medicine nejm.org/doi/10.1056/NE…

david corenswet for people

🫀 Does lowering heart rate improve outcomes in hypertension? 📊 Meta-analysis 74 trials Benefits only in In post-MI or HF target 65-70bpm: · ↓ Coronary heart disease: -16% · ↓ Heart failure: -9% · ↓ CV mortality: -14% · ↓ All-cause mortality: -13% academic.oup.com/eurheartj/arti…

Cómo calcular tamaño muestral en estudios clínicos? Información clave!! frontiersin.org/journals/medic…

Among patients undergoing stem-cell transplantation from matched related donors, cyclophosphamide plus cyclosporin led to significantly longer GVHD-free, relapse-free survival than standard prophylaxis. Full ALLG BM12 CAST phase 3 trial results and Research Summary:

Apenas es Martes y yo ya pasé por todo el rango de emociones humanas esta semana.

🔴Cardiac rhythm devices in heart failure with reduced ejection fraction – 😍🩸⤵️ 🔬2025 Expert consensus document DIRECT-HF initiative #ESC_HF #OpenAccess 🔹onlinelibrary.wiley.com/doi/10.1002/ej… #MedEd #MedX #Diagnosis #Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology

🤍

Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-analysis published in #EHJ ow.ly/GhXT50WrMHA Rocco Montone EHJ Editor-in-Chief

Worse #CVD risk scores or cardiovascular health metrics predict greater cancer risk, despite heterogeneity in CVD risk metrics & cancer types, according to a study published in #JACCCardioOnc. Read the journal scan to learn more: bit.ly/3GCQUb1 #CardioOnc JACC Journals

Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis Although 10 000 steps per day can still be a viable target for those who are more active, 7000 steps per day is associated with clinically meaningful improvements in health outcomes

New in the July 24, 2025, issue of NEJM: Fixed-Dose Insulin Efsitora in Type 2 Diabetes (QWINT-1 phase 3 trial) nej.md/4jX5R59 Trastuzumab Deruxtecan in Gastric Cancer (DESTINY-Gastric04 phase 3 trial) nej.md/4k1dwjN Tarlatamab in Small-Cell Lung Cancer

😍